JankovicV1, Ncbi, Checkpoint, bibRecord, 000103

Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial

Identifieur interne : 000103 ( Ncbi/Checkpoint ); précédent : 000102; suivant : 000104

Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial

Auteurs : W. Ondo ; R. Fayle ; F. Atassi ; Joseph Jankovic [États-Unis]

Source :

Journal of Neurology, Neurosurgery, and Psychiatry [ 0022-3050 ] ; 2005.

RBID : PMC:1739456

English descriptors

KwdEn :
- Aged, Benzhydryl Compounds (therapeutic use), Central Nervous System Stimulants (therapeutic use), Disorders of Excessive Somnolence (drug therapy), Disorders of Excessive Somnolence (etiology), Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Placebos, Severity of Illness Index, Treatment Outcome.
MESH :
- chemical , therapeutic use : Benzhydryl Compounds, Central Nervous System Stimulants.
- complications : Parkinson Disease.
- drug therapy : Disorders of Excessive Somnolence, Parkinson Disease.
- etiology : Disorders of Excessive Somnolence.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Severity of Illness Index, Treatment Outcome.

Abstract

Background: Excessive daytime somnolence (EDS) commonly complicates Parkinson's disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions.

Method: A double blind, placebo controlled parallel design trial was conducted to assess the efficacy of modafinil (200–400 mg/day) for the treatment of EDS in PD. The primary efficacy measure was the Epworth Sleepiness (ES) scale score. Secondary efficacy points included the Unified Parkinson's Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, and the multiple sleep latency test (MSLT).

Results: Of a total of 40 subjects (29 men, mean (SD) age 64.8 (11.3) years), randomised to modafinil or placebo, 37 completed the study. Modafinil failed to significantly improve ES scores compared with placebo (2.7 v 1.5 points improvement, respectively, p = 0.28). MSLT failed to improve with modafinil relative to placebo (–0.16 v –0.70, respectively, p = 0.14). UPDRS, global impressions, Fatigue Severity Scale, and Hamilton Depression Scale scores were unchanged. Adverse events were minimal.

Conclusion: Modafinil failed to significantly improve EDS in PD compared with placebo. The drug did not alter motor symptoms in PD and was well tolerated.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1739456

DOI: 10.1136/jnnp.2005.065870
PubMed: 16291885
PubMed Central: 1739456

Affiliations:

Links to Exploration step

PMC:1739456

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial</title>
<author><name sortKey="Ondo, W" sort="Ondo, W" uniqKey="Ondo W" first="W" last="Ondo">W. Ondo</name>
</author>
<author><name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R. Fayle</name>
</author>
<author><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F. Atassi</name>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">16291885</idno>
<idno type="pmc">1739456</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1739456</idno>
<idno type="RBID">PMC:1739456</idno>
<idno type="doi">10.1136/jnnp.2005.065870</idno>
<date when="2005">2005</date>
<idno type="wicri:Area/Pmc/Corpus">000230</idno>
<idno type="wicri:Area/Pmc/Curation">000230</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000267</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000187</idno>
<idno type="wicri:Area/PubMed/Curation">000187</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000194</idno>
<idno type="wicri:Area/Ncbi/Merge">000103</idno>
<idno type="wicri:Area/Ncbi/Curation">000103</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000103</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial</title>
<author><name sortKey="Ondo, W" sort="Ondo, W" uniqKey="Ondo W" first="W" last="Ondo">W. Ondo</name>
</author>
<author><name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R. Fayle</name>
</author>
<author><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F. Atassi</name>
</author>
<author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Neurology, Neurosurgery, and Psychiatry</title>
<idno type="ISSN">0022-3050</idno>
<idno type="e-ISSN">1468-330X</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Benzhydryl Compounds (therapeutic use)</term>
<term>Central Nervous System Stimulants (therapeutic use)</term>
<term>Disorders of Excessive Somnolence (drug therapy)</term>
<term>Disorders of Excessive Somnolence (etiology)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Placebos</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Benzhydryl Compounds</term>
<term>Central Nervous System Stimulants</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Disorders of Excessive Somnolence</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Disorders of Excessive Somnolence</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Placebos</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><bold>Background:</bold>
 Excessive daytime somnolence (EDS) commonly complicates Parkinson's disease (PD). The aetiology of EDS is probably multifactorial but is probably exacerbated by dopaminergic medications. Modafinil is a wake-promoting agent approved for use in narcolepsy, but it is often used to treat a variety of somnolent conditions. </p>
<p><bold>Method:</bold>
 A double blind, placebo controlled parallel design trial was conducted to assess the efficacy of modafinil (200–400 mg/day) for the treatment of EDS in PD. The primary efficacy measure was the Epworth Sleepiness (ES) scale score. Secondary efficacy points included the Unified Parkinson's Disease Rating Scale (UPDRS), the Fatigue Severity Scale, the Hamilton Depression Scale, and the multiple sleep latency test (MSLT). </p>
<p><bold>Results:</bold>
 Of a total of 40 subjects (29 men, mean (SD) age 64.8 (11.3) years), randomised to modafinil or placebo, 37 completed the study. Modafinil failed to significantly improve ES scores compared with placebo (2.7 <italic>v</italic>
 1.5 points improvement, respectively, p = 0.28). MSLT failed to improve with modafinil relative to placebo (–0.16 <italic>v</italic>
 –0.70, respectively, p = 0.14). UPDRS, global impressions, Fatigue Severity Scale, and Hamilton Depression Scale scores were unchanged. Adverse events were minimal. </p>
<p><bold>Conclusion:</bold>
 Modafinil failed to significantly improve EDS in PD compared with placebo. The drug did not alter motor symptoms in PD and was well tolerated. </p>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
<settlement><li>Houston</li>
</settlement>
<orgName><li>Baylor College of Medicine</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Atassi, F" sort="Atassi, F" uniqKey="Atassi F" first="F" last="Atassi">F. Atassi</name>
<name sortKey="Fayle, R" sort="Fayle, R" uniqKey="Fayle R" first="R" last="Fayle">R. Fayle</name>
<name sortKey="Ondo, W" sort="Ondo, W" uniqKey="Ondo W" first="W" last="Ondo">W. Ondo</name>
</noCountry>
<country name="États-Unis"><region name="Texas"><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">Joseph Jankovic</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Ncbi/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000103 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000103 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    RBID
   |clé=     PMC:1739456
   |texte=   Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i   -Sk "pubmed:16291885" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a JankovicV1

This area was generated with Dilib version V0.6.19.
Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024

Serveur d'exploration autour de Joseph Jankovic

Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial

Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration autour de Joseph Jankovic
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.